Welcome to our dedicated page for Acumen Pharmaceuticals news (Ticker: ABOS), a resource for investors and traders seeking the latest updates and insights on Acumen Pharmaceuticals stock.
Acumen Pharmaceuticals, Inc. develops clinical-stage Alzheimer’s disease therapeutics that target toxic soluble amyloid beta oligomers. The company’s recurring updates center on sabirnetug (ACU193), a humanized monoclonal antibody program, the ALTITUDE-AD and INTERCEPT-AD clinical study framework, and research on biomarkers and antibody selectivity.
Company news also covers Enhanced Brain Delivery (EBD™) work using transferrin-receptor-targeting blood-brain barrier technology, subcutaneous formulation research using ENHANZE® drug delivery technology, collaborations, conference presentations, operating results, financing activity, and management participation in health care and CNS investor events.
Acumen Pharmaceuticals, focusing on Alzheimer’s disease therapeutics, achieved a significant milestone by enrolling the first patients in the INTERCEPT-AD Phase 1 clinical trial for its investigational drug, ACU193. This humanized monoclonal antibody selectively targets toxic amyloid-beta oligomers (AβOs). Despite delays attributed to the COVID-19 Delta variant, Acumen expects to report topline data by the end of 2022. The company reported a net loss of $92.3 million for the nine-month period ending September 30, 2021, with cash and cash equivalents totaling $135.8 million.
Acumen Pharmaceuticals, a clinical stage biopharmaceutical company focused on Alzheimer's disease, announced participation in two upcoming virtual conferences. The first is the Credit Suisse 30th Annual Healthcare Conference on November 9, 2021, at 9:40 AM EST, followed by the Stifel 2021 Healthcare Conference on November 16, 2021, at 10:00 AM EST. Live webcasts will be accessible on-demand for 30 days after each event on their website. Acumen is advancing its investigational product ACU193, targeting toxic AβOs in early Alzheimer's patients.
Acumen Pharmaceuticals (NASDAQ: ABOS) announced its participation in the 2021 Clinical Trials on Alzheimer’s Disease (CTAD) conference, where it will present on its investigational drug ACU193. This monoclonal antibody targets toxic amyloid-beta oligomers, a key factor in Alzheimer’s disease pathology. The INTERCEPT-AD trial, currently enrolling early Alzheimer’s patients, aims to assess safety and cognitive improvements. The presentation is scheduled for November 10, 2021, and emphasizes ACU193's potential to modify disease progression with improved synaptic function.
Acumen Pharmaceuticals has initiated dosing in its Phase 1 clinical trial, INTERCEPT-AD, for ACU193, a monoclonal antibody targeting toxic amyloid-beta oligomers in early Alzheimer’s patients. This trial aims to establish safety, pharmacokinetics, and target engagement and will enroll approximately 62 participants. The CEO expressed optimism regarding ACU193's potential to meet unmet medical needs in Alzheimer’s treatment, highlighting its unique mechanism compared to other monoclonal antibodies.
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) reported Q2 2021 financial results, highlighting substantial progress in its clinical trial for ACU193, which targets toxic amyloid-beta oligomers linked to Alzheimer’s disease. The company closed an IPO in July 2021, raising approximately $168.6 million, boosting cash reserves to over $235 million. R&D expenses rose to $2.3 million for Q2 2021, while net losses surged to $61.4 million, largely due to non-cash expenses related to warrant liabilities. The ongoing Phase 1 trial, ACU-001, is expected to yield top-line results by the end of 2022.
Acumen Pharmaceuticals (Nasdaq: ABOS) has priced its upsized initial public offering (IPO) of 9,999,999 shares at $16.00 each, raising approximately $160 million before expenses. The offering will close on July 6, 2021, with shares expected to start trading on July 1, 2021. Acumen has granted underwriters a 30-day option for an additional 1,499,999 shares. The funds will support the development of ACU193, a therapy targeting Alzheimer’s disease. The company initiated a Phase 1 clinical trial for ACU193 in Q2 2021, with results expected by the end of 2022.